Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma

European Journal of Haematology

Volumn 61, Issue 2, 1998, Pages 128-134

  Abildgaard, N ^a   Rungby, J ^a   Glerup, H ^a   Brixen, K ^a   Kassem, M ^a   Brincker, H ^b   Heickendorff, L ^a   Eriksen, E F ^a   Nielsen, J L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bone histomorphometry; Cytokine network; Multiple myeloma; Osteoclastic activity; Pamidronate

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; PAMIDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BONE DEVELOPMENT; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

EID: 0031876780     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01073.x     Document Type: Article

References (47)

1. MUNDY GR, RAISZ LG, COOPER RA, SCHECHTER GP, SALMON SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974: 291: 1041-1045.
2. BATAILLE R, CHAPPARD D, MARCELLI C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989: 7: 1909-1914.
3. KLEIN B, BATAILLE R. Cytokine network in human multiple myeloma. Hematol/Oncol Clin N Am 1992: 6: 273-284.
4. KAWANO M, YAMAMOTO I, IWATO K, et al. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activator in human multiple myeloma. Blood 1989: 73: 1646-1649.
5. CARTER A, MERCHOV S, SILIVAN-DRAXLER I, TATARSKY I. The role of interleukin-1 and tumour necrosis factor-alfa in human multiple myeloma. Br J Haematol 1990: 74: 424-431.
6. BATAILLE R, KLEIN B, JOURDAN M, ROSSI J, DURIE BGM. Spontaneous secretion of tumour necrosis factor-beta by human myeloma cell lines. Cancer 1989: 63: 877-880.
7. GARRETT IR, DURIE BGM, NEDWIN GE, et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987: 317: 526-532.
8. LICHTENSTEIN A, BERENSON J, NORMAN D, CHANG MP, CARLILE A. Production of cytokines by marrow cells obtained from patients with multiple myeloma. Blood 1989: 74: 1266-1273.
9. MUNDY GR, BOYCE B, HUGHES D, et al. The effects of cytokines and growth factors on osteoblastic cells. Bone 1995: 17 (suppl 2): 71S-75S.
10. ANDERSON KC, JONES RM, MORIMOTO C, LEAVITT P, BARUT BA. Response pattern of purified myeloma cells to hematopoietic growth factors. Blood 1989: 73: 1915-1924.
11. ZHANG XG, KLEIN B, BATAILLE R. Interleukin 6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989: 74: 11-13.
12. KISHIMOTO T, TAGA T, AKIRA S. Cytokine signal transduction. Cell 1994: 76: 253-262.
13. LUDWIG H, NACHBAUER DM, FRITZ E, KRAINER M, HUBER H. Interleukin 6 is a prognostic factor in multiple myeloma. Blood 1991: 77: 2794-2795.
14. PELLNIEMI TT, IRJALA K, MATTILA K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995: 85: 765-771.
15. PULKKI K, PELLINIEMI TT, RAJAMÄKI A, TIENHAARA A, LAAKSO M, LAHTINEN R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol 1996: 92: 370-374.
16. COLEMAN RE, PUROHIT OP. Osteoclast inhibition for the treatment of bone métastases. Cancer Treatment Rev 1993: 19: 79-103.
17. BERENSON JR, LICHTKNSTEIN A, PORTER L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996: 334: 488-493.
18. BELCH AR, BERGSAGEL DE, WILSON K, et al. Effect of daily etidronate on the ostcolysis of multiple myeloma. J Clin Oncol 1991: 9: 1397-1402.
19. LAHTINEN R, LAAKSO M, PALVA I, VIRKKUNEN P, ELOMAA I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992: 340: 1049-1052.
20. BRINCKER H, WESTIN J, ABILDGAARD N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 1998: in press.
21. FITTON A, MCTAVISH D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991: 41: 289-318.
22. ABILDGAARD N, NIELSEN JL, HEICKENDORFF L. Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. Am J Hematol 1994: 46: 173-178.
23. ERIKSEN EF, BRIXEN K, CHARLES P. New markers of bone metabolism: clinical use in metabolic bone disease. Eur J Endocrinol 1995: 132: 251-263.
24. WITHOLD W. Monitoring of bone turnover. Biological, preanalytical and technical criteria in the assessment of biochemical markers. Eur J Clin Chem Clin Biochem 1996: 34: 785-799.
25. DURIE BGM, SALMON SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975: 36: 842-854.
26. ERIKSEN EF. Normal and pathological remodelling of human trabecular bone: three-dimensional reconstruction of the remodelling cycle in normals and in metabolic bone disease. Endoc Rev 1986: 7: 379-408.
27. PARFITT AM, DREZNER MK, GLORIEOEX FH, et al. Bone histomorphometry: standardization of nomenclature, symbols and units. J Bone Min Res 1987: 2: 595-610.
28. RISTELI J, ELOMAA I, NIEMI S, NOVAMO A, RISTELI L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993: 39: 635-640.
29. BLACK D, DUNCAN A, ROBBINS SP. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Ann Biochem 1988: 169: 197-203.
30. HANSON DA, WEIS MAE, BOLLEN A, MASEAN SL, SINGER FR, EYRK DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Min Res 1992: 7: 1251-1258.
31. MELKKO J, NIEMI J, RISTELI L, RISTELI J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990: 36: 1328-1332.
32. PRICE PA, NISHIMOTO SK. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Science 1980: 77: 2234-2238.
33. BEHR W, BARNERT J. Quantitation of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility. Clin Chem 1986: 32: 1960-1966.
34. SATO M, GRASSER W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Min Res 1990: 5: 31-40.
35. HUGHES DE, WRIGMT KR, U HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Min Res 1995: 10: 1478-1487.
36. CARANO A, TEITELBAUM SL, KONSEK JD, SCHLESINGER PH, BLAIR HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990: 85: 456-461.
37. LÖWIK CWGM, VAN DER PLUUM G, VAN DER WEE-PALS LJA, VAN TRESLONG-DE GROOT HB, BIJVOET OLM. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Min Res 1988: 3: 185-192.
38. HUGHES DE, MACDONALD BR, RUSSELL RGG, GOWEN M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989: 83: 1930-1935.
39. BATAILLE R, CHAPPARD D, BASLE M. Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo. Br J Haematol 1995: 90: 721-724.
40. KLEIN B. Cytokines, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin Hematol 1995: 32: 4-19.
41. KLEIN B, ZHANG X, JOURDAN M, et al. Paracrine rather than autocrinc regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989: 73: 517-526.
42. BØRSET M, HELSETH E, NAUME B, WAAGE A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br J Haematol 1993: 85: 446-451.
43. BERENSON JR, LICHTENSTEIN A, PORTER L, et al. Long-term pamidronate disodium therapy leads to a reduction of skeletal related episodes (SREs) in stage III multiple myeloma patients and an improvement in survival in those on salvage therapy. Blood 1995: 86 (suppl 1): 442a.
44. PASSERI G, GIRASOLE G, ULIETTI V, et al. Bisphosphonates inhibit IL-6 production by human osteoblast cells MG-63. J Bone Mineral Res 1994: 9 (suppl 1): S230.
45. SHIPMAN CM, ROGERS MJ, APPERLEY JF, RUSSELL GG, CROUCHKR PI. Bisphosphonates induce apoptosis in human myeloma ell lines: a novel anti-tumour activity. Br J Haematol 1997: 98: 665-672.
46. TAUBE T, BENETON MNC, MCCLOSKEY EV, ROGERS S, GREAVES M, KANIS JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992: 49: 192-198.
47. EVANS CE, ALLEN J, PARKER J. Adhesion of human osteoblast-like cells in culture is impaired by exposure to factors secreted by multiple myeloma cells. Eur J Musculoskel Res 1994: 3: 137-144.